Contact | Print version | PDF version | Send article | RSS feed

Biosite and FivePrime Announce Antibody Collaboration

23 Feb 2006 - Biosite Incorporated and Five Prime Therapeutics, Inc. have entered into a collaboration for the evaluation of disease targets for potential commercialization of diagnostic and therapeutic products.
 
Under the collaboration, FivePrime will provide Biosite access to selected functional disease targets for use in developing diagnostics. In exchange, Biosite will provide FivePrime with Omniclonal(R) antibodies for selected targets to accelerate FivePrime's therapeutic research efforts. Biosite's proprietary antibody development process generates highly diverse libraries of Omniclonal antibodies with high affinity and low cross-reactivity.
 
The financial terms of the agreement were not disclosed.